The
tachykinins substance P and
neurokinin A (NKA) are present in sensory airway nerves and have been implicated in the pathogenesis of
asthma.
FK224 is a
cyclopeptide tachykinin antagonist previously shown to inhibit both
tachykinin NK-1 and
NK-2 receptor mediated airway responses in guinea pigs. Inhaled
FK224 protected against
bradykinin-induced bronchoconstriction and
cough in asthmatics. In this study we examined the reproducibility of the NKA challenge and the effect of inhaled
FK224 on NKA-induced bronchoconstriction in 10 patients with stable
asthma. On Day 1 baseline lung function and PC20
methacholine were determined. On Days 2 and 3 increasing doubling concentrations of NKA (3.3 x 10(-9) to 1.0 x 10(-6) mol/ml) were administered via inhalation, with intervals of 10 min. On both days NKA caused a concentration-dependent decrease in specific airways conductance (sGaw) and FEV1. Mean +/- SEM, log PC35, sGaw NKA (mol/ml) was -6.61 +/- 0.10 on Day 2 and -6.57 +/- 0.14 on Day 3 (not significant [NS]). On Days 4 and 5
FK224 (4 mg) or placebo (P) was administered via
metered-dose inhaler 30 min before NKA challenge in a double-blind, crossover manner. The study medication was well tolerated.
FK224 had no significant effect on baseline lung function. After P and
FK224, NKA caused a comparable concentration-dependent bronchoconstriction. The mean +/- SEM log PC35 sGaw NKA (mol/ml) was -6.04 +/- 0.18 after P and -6.19 +/- 0.23 after
FK224 (NS). In conclusion, inhaled
FK224 had no effect on baseline lung function and offered no protection against NKA-induced bronchoconstriction in a group of mild asthmatic patients.